| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8726902 | Gastroenterology | 2018 | 49 Pages |
Abstract
We compared RASs in NS3, NS5A, and NS5B among patients failed by DAA therapy. Theses varied with the HCV genotype and subtype, and the different drug classes. These findings might be used to select salvage therapies.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Julia Dietz, Simone Susser, Johannes Vermehren, Kai-Henrik Peiffer, Georgios Grammatikos, Annemarie Berger, Peter Ferenci, Maria Buti, Beat Müllhaupt, Bela Hunyady, Holger Hinrichsen, Stefan Mauss, Jörg Petersen, Peter Buggisch, Gisela Felten,